Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Perrigo Company PLC

Healthcare US PRGO

11.115USD
-0.495(4.26%)

Last update at 2026-06-09T15:05:00Z

Day Range

10.8911.56
LowHigh

52 Week Range

26.5739.61
LowHigh

Fundamentals

  • Previous Close 11.61
  • Market Cap4295.54M
  • Volume1325629
  • P/E Ratio396.25
  • Dividend Yield3.44%
  • EBITDA654.20M
  • Revenue TTM4654.00M
  • Revenue Per Share TTM34.45
  • Gross Profit TTM 1455.40M
  • Diluted EPS TTM0.08

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -139.10000M 258.70M -149.40000M 171.00M 290.60M
Minority interest - - - 0.30M 0.10M
Net income -130.90000M -130.90000M -162.60000M 146.10M 131.00M
Selling general administrative 512.30M 482.00M 496.00M 503.00M 435.90M
Selling and marketing expenses 697.80M 629.40M 679.50M 663.10M 689.90M
Gross profit 1455.40M 1416.20M 1815.20M 1773.30M 1831.50M
Reconciled depreciation 338.60M 312.20M 384.80M 396.50M 423.60M
Ebit 172.80M 573.70M 932.40M 604.50M 539.10M
Ebitda 511.40M 885.90M 1317.20M 1001.00M 962.70M
Depreciation and amortization 338.60M 312.20M 384.80M 396.50M 423.60M
Non operating income net other - -26.70000M -133.60000M 87.90M 182.10M
Operating income 172.80M 573.70M 932.40M 604.50M 236.50M
Other operating expenses 4330.20M 3538.30M 4597.60M 4421.80M 4249.80M
Interest expense 156.00M 125.00M 125.00M 121.70M 128.00M
Tax provision -8.20000M 389.60M 13.20M 24.90M 159.60M
Interest income - - 131.20M 96.30M 120.40M
Net interest income -156.00000M -125.00000M -131.20000M -121.70000M -128.00000M
Extraordinary items - - - - -
Non recurring - 190.00M 350.30M 210.80M 245.40M
Other items - - - - -
Income tax expense -8.20000M 389.60M 13.20M 24.90M 159.60M
Total revenue 4451.60M 4138.70M 5063.30M 4837.40M 4731.70M
Total operating expenses 1334.00M 815.80M 1349.50M 1357.70M 1349.60M
Cost of revenue 2996.20M 2722.50M 3248.10M 3064.10M 2900.20M
Total other income expense net -311.90000M -315.00000M -1081.80000M -433.50000M -63.30000M
Discontinued operations -9.70000M 62.00M 62.00M 62.00M 62.00M
Net income from continuing ops -130.90000M -130.90000M -162.60000M 146.10M 131.00M
Net income applicable to common shares -140.60000M -68.90000M -162.60000M 146.10M 131.00M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 11017.30M 10425.70M 11488.40M 11301.40M 10983.40M
Intangible assets 3230.20M 2146.10M 2974.30M 2921.20M 2858.90M
Earning assets - - - - -
Other current assets 271.80M 321.90M 237.60M 192.10M 400.00M
Total liab 6175.20M 5274.00M 5833.30M 5497.30M 5315.30M
Total stockholder equity 4842.10M 5151.70M 5655.10M 5803.80M 5668.00M
Deferred long term liab - 239.30M 279.30M 280.60M 282.30M
Other current liab 533.00M 32.90M 800.40M 812.20M 872.30M
Common stock 6936.70M 7043.20M 7118.20M 7359.90M 7421.70M
Capital stock 6936.70M 7043.20M 7118.20M 7359.90M 7421.70M
Retained earnings -2067.60000M -1927.00000M -1858.10000M -1695.50000M -1838.30000M
Other liab 801.70M 769.40M 923.00M 694.00M 725.70M
Good will 3549.00M 3004.70M 3783.90M 4185.50M 4029.10M
Other assets 240.20M 384.00M 3576.00M 357.40M 344.60M
Cash 600.70M 1864.90M 641.50M 354.30M 551.10M
Cash and equivalents - - - - -
Total current liabilities 1113.60M 1587.90M 1382.00M 1335.80M 1537.40M
Current deferred revenue 7.10M 540.00M 44.00M - -
Net debt 3505.90M 1655.60M 2924.60M 3014.90M 2691.30M
Short term debt 36.20M 603.80M 37.80M 3.40M 190.20M
Short long term debt 36.20M 603.80M 37.80M 3.40M 190.20M
Short long term debt total 4106.60M 3520.50M 3566.10M 3369.20M 3242.40M
Other stockholder equity 6936.70M 7043.00M 395.00M 0.40M -0.40000M
Property plant equipment 1165.40M 1031.00M 996.00M 902.80M 829.10M
Total current assets 2719.90M 3859.90M 3133.50M 2756.90M 2902.20M
Long term investments - - - 20.10M 19.50M
Net tangible assets -1937.10000M 0.90M 2680.80M 2882.60M 2809.10M
Short term investments - - - 6.60M 9.40M
Net receivables 697.10M 652.90M 1054.20M 1243.20M 1073.10M
Long term debt 4070.40M 2916.70M 3528.30M 3365.80M 3052.20M
Inventory 1150.30M 1020.20M 1200.20M 967.30M 878.00M
Accounts payable 537.30M 411.20M 543.80M 520.20M 474.90M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - 0.30M 0.10M
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -27.00000M 35.50M 395.00M 139.40M 84.60M
Additional paid in capital - - - - -
Common stock total equity - 7043.20M 7118.20M 7359.90M 7421.70M
Preferred stock total equity - - - - -
Retained earnings total equity - -1927.00000M -1858.10000M -1695.50000M -1838.30000M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 367.70M 377.50M 370.50M 399.70M 362.90M
Deferred long term asset charges - - - - -
Non current assets total 8297.40M 6565.80M 8354.90M 8544.50M 8081.20M
Capital lease obligations 189.50M 173.30M - - -
Long term debt total - 2916.70M 3528.30M 3365.80M 3052.20M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -1958.60000M 1275.80M -15.00000M -596.10000M -7.50000M
Change to liabilities 100.30M -7.90000M -2.70000M 17.00M 28.80M
Total cashflows from investing activities -1958.60000M 1275.80M -187.80000M -596.10000M -126.80000M
Net borrowings 616.70M -30.60000M 124.20M 123.50M -58.30000M
Total cash from financing activities 421.60M -178.70000M -181.10000M 1.80M -571.90000M
Change to operating activities 44.20M -77.70000M -57.80000M -48.30000M -38.70000M
Net income -140.60000M -68.90000M -162.60000M 146.10M 131.00M
Change in cash -1264.20000M 1233.40M 287.20M -196.80000M -127.60000M
Begin period cash flow 1864.90M 631.50M 354.30M 551.10M 678.70M
End period cash flow 600.70M 1864.90M 641.50M 354.30M 551.10M
Total cash from operating activities 307.30M 156.30M 636.20M 387.80M 593.00M
Issuance of capital stock - 0.00000M - 0.90M 1.30M
Depreciation 338.60M 312.20M 384.80M 396.50M 423.60M
Other cashflows from investing activities 61.70M 2.80M -2.40000M -309.30000M -16.70000M
Dividends paid 142.40M 129.60M 123.90M 112.40M 104.90M
Change to inventory -76.70000M -2.40000M -170.60000M -67.00000M -98.60000M
Change to account receivables 0.10M -159.70000M 168.90M -140.70000M 21.00M
Sale purchase of stock 0.00000M 0.00000M -164.20000M 600.50M -400.00000M
Other cashflows from financing activities 1522.90M -49.10000M -23.90000M -11.20000M 418.60M
Change to netincome 89.30M 208.40M 705.40M 701.30M 612.40M
Capital expenditures 96.40M 152.10M 170.40M 137.70M 102.60M
Change receivables - - - - -
Cash flows other operating - -295.40000M -69.20000M -313.50000M -19.40000M
Exchange rate changes - - - - -21.90000M
Cash and cash equivalents changes - 1253.40M 267.30M -206.50000M -127.60000M
Change in working capital 20.00M -295.40000M -69.20000M -313.50000M -19.40000M
Stock based compensation 54.90M 60.10M 58.50M 52.20M 37.70M
Other non cash items 84.90M 138.90M 479.20M 150.40M 38.00M
Free cash flow 210.90M 4.20M 465.80M 250.10M 490.40M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
PRGO
Perrigo Company PLC		 -0.495 4.26% 11.12 396.25 10.36 0.90 0.88 1.69 13.66
ZTS
Zoetis Inc		 -0.62 0.78% 78.82 40.18 30.96 10.67 17.60 11.27 26.18
MKKGY
Merck KGaA ADR		 0.28 0.89% 31.62 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 -4.068 2.48% 159.71 21.73 14.95 3.16 2.15 3.56 12.82
GALDY
GALDERMA GROUP AG		 1.19 2.94% 41.64 74.21 41.67 8.64 5.55 9.15 42.22

Reports Covered

Stock Research & News

View All

Profile

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in Ireland, the United States, France, Belgium, China, the United Kingdom, Germany, Switzerland, Austria, Italy, Australia, Greece, and Spain. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The Consumer Self-Care Americas segment develops, manufacture, and markets self-care products including upper respiratory, pain and sleep-aids, digestive health, nutrition, healthy lifestyle, skincare, women's health, and other products, as well as vitamins, minerals and supplements, and oral self-care in the United States and Canada. This segment offers its products under Burt's Bees, Compeed, Dr. Fresh, Firefly, Good Sense, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, and Steripod brands. Consumer Self-Care International segment comprises consumer self-care product categories outside the U.S. and Canada, including branded products in Europe and Australia, and store brand products in the United Kingdom and parts of Europe and Asia, which develops, manufactures, markets, and distributes consumer self-care brands through a network of drug and grocery store retailers, e-commerce stores, and para-pharmacies in more than 29 countries, primarily in Europe. In addition, the company offers contract manufacturing services. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.

Perrigo Company PLC

The Sharp Building, Dublin, Ireland, 2

Key Executives

Name Title Year Born
Mr. Murray S. Kessler CEO, Pres & Director 1960
Mr. Svend Andersen Exec. VP & Pres of Consumer Self-Care International 1962
Mr. James E. Dillard III Exec. VP & Pres of Consumer Self-Care Americas 1964
Mr. Eduardo Guarita Bezerra Exec. VP & CFO 1975
Mr. Ronald C. Janish Chief Transformation Officer and Exec. VP of Global Operations & Supply Chain 1966
Mr. Shannon Hukill Sr. Director of Technical Operations NA
Mr. Thomas M. Farrington Chief Information Officer & Exec. VP 1957
Ms. Alison Ives Exec. VP & Chief Scientific Officer NA
Mr. Bradley Joseph VP of Global Investor Relations & Corp. Communications NA
Ms. Kyle L. Hanson Exec. VP, Gen. Counsel & Corp. Sec. 1965

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.